In December, Sepracor's Lunesta became the first sleeping pill approved without a restriction, limiting its use for a week or so, on its label. (Ambien has such a limitation, though many doctors prescribe it for longer.) Indiplon, being developed by Neurocrine and Pfizer, is likely to get similar labeling.